Is a nasal vaccine for Alzheimer's on the horizon?A new phase 1 trial of a nasal vaccine for Alzheimer’s disease is beginning. Scientists have used the vaccine with success in mouse models that simulate some of the characteristics of Alzheimer’s.

If the new trial shows the vaccine to be safe in humans, further studies will test whether it is also effective.


Alzheimer’s disease is a neurodegenerative condition and the most commonTrusted Source type of dementia.

People with the disease typically develop the symptoms after the age of 60. Alzheimer’s is characterized by the progressive loss of cognitive functioning, and when it is most severe, a person may not be able to respond to the world around them.

An estimated 5.8 millionTrusted Source people in the United States had Alzheimer’s disease in 2020, and it is the sixth leading cause of death in adults.

There is currently no cure for Alzheimer’s, and treatments usually focus on helping people manage its symptoms.

A ‘remarkable milestone’?

Scientists from the Brigham and Women’s Hospital, in Boston, are now starting a phase 1 clinical trial to see whether a potential treatment could be safe for humans.

Previously, the team showed that the nasal vaccine could prevent and treat the disease in a mouse model that simulates Alzheimer’s. These studies were published in 2005, 2008, and 2012.

Read more…